2025
Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsAdoption of Broad Genomic Profiling in Patients With Cancer
Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.Peer-Reviewed Original ResearchUse of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.
Wang X, Long J, Rothen J, Huang S, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Ma S, Wang S, Kunst N, Dinan M, Gross C. Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. Journal Of Clinical Oncology 2025, 43: 11155-11155. DOI: 10.1200/jco.2025.43.16_suppl.11155.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerTargeted therapyLung cancerTargetable alterationsGenomic profilingUsefulness of targeted therapyUS cancer clinicsFirst-line treatmentCohort of patientsClinico-genomic databaseNCCN GuidelinesIdentified patientsPatient populationFDA approvalTreatment selectionPatientsCancer clinicClinical guidelinesTherapyCancerLimited dataTT useFDA approval statusFactors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis.
Forman R, Wang R, Yasin F, Kwaramba T, Lacy J, Ma X, Dinan M. Factors associated with decreased treatment intensity in patients with metastatic colon cancer: A real world analysis. Journal Of Clinical Oncology 2025, 43: 11168-11168. DOI: 10.1200/jco.2025.43.16_suppl.11168.Peer-Reviewed Original ResearchMetastatic colon cancerNon-intensive therapyNational Comprehensive Cancer NetworkPoor performance statusIntensive therapyFlatiron Health electronic health record-derived deidentified databaseColon cancerIntensive first-line therapyUndertreatment of older patientsNational Comprehensive Cancer Network guidelinesOdds ratioAssociated with treatment choiceFirst-line therapyAssociated with female sexComprehensive Cancer NetworkRetrospective cohort studyYear of diagnosisShorter overall survivalNon-frail patientsOlder ageNon-frailMultivariate logistic regressionEstimate odds ratiosAssociated with receiptTreatment intensityRisk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors.
Kwaramba T, Westvold S, Long J, Hyslop T, Silber A, Lustberg M, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Dinan M. Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors. Journal Of Clinical Oncology 2025, 43: 1642-1642. DOI: 10.1200/jco.2025.43.16_suppl.1642.Peer-Reviewed Original ResearchSurvivors of breastRectal cancer survivorsCancer survivorsYears post-diagnosisPost-diagnosisOlder survivorsScreen-detectedSEER-MedicareLong-term cancer survivorsNon-screened cancersLong-term breastStage I-III cancerProstate cancer survivorsIndex cancer diagnosisContinuous Medicare Parts ASEER-Medicare dataModifiable risk factorsMedicare Part ADiagnosis of SPMSurvivorship careSEER-Medicare databaseSurvivorship cohortScreening guidelinesAssociated with shorter timeIndex cancerScreening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer
Huang S, Westvold S, Soulos P, Fan J, Winer E, Zhan H, Lustberg M, Lewin J, Robinson T, Dinan M. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Network Open 2025, 8: e255322. PMID: 40232715, PMCID: PMC12000969, DOI: 10.1001/jamanetworkopen.2025.5322.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityBreast cancer mortalityBreast cancer diagnosisCancer-specific mortalityCancer mortalityCancer diagnosisScreening mammographyHazard of breast cancer-specific deathFee-for-service Medicare Parts AAssociated with reduced breast cancer mortalityLower breast cancer mortalityHazard of breast cancer-specific mortalityBreast cancerImprove breast cancer outcomesScreen-detected breast cancerCohort studyBreast cancer-specific deathStudy of older womenBreast cancer outcomesFee-for-serviceDetection of breast cancerMedicare Part ALater-stage diseaseCox proportional hazards modelsAssociated with early stagesBPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era.
Wang X, Long J, Rothen J, Soulos P, Robinson T, Presley C, Goldberg S, Mamtani R, Wang S, Kunst N, Ma S, Huang S, Gross C, Dinan M. BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 40154428, DOI: 10.6004/jnccn.2024.7205.Peer-Reviewed Original ResearchOff-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma
McManus H, Long J, Westvold S, Leapman M, Hurwitz M, Mitchell A, Pollack C, Gross C, Dinan M. Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2025, 23: 102330. PMID: 40186898, PMCID: PMC12084128, DOI: 10.1016/j.clgc.2025.102330.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaImmune checkpoint inhibitorsFood and Drug AdministrationRenal cell carcinomaOff-labelCell carcinomaOlder patientsImmune checkpoint inhibitor useFood and Drug Administration approvalFirst-line immunotherapyMultivariate logistic regressionOff-label useCo-morbid conditionsCheckpoint inhibitorsFirst-lineCo-morbiditiesDrug AdministrationPatientsCo-morbidityPostapproval settingLogistic regressionCarcinomaDemographic characteristicsPostapprovalPostapproval periodPersonalized frailty risk assessment in long-term survivors of colorectal cancer.
Forman R, Westvold S, Long J, Fan J, Hyslop T, Yasin F, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized frailty risk assessment in long-term survivors of colorectal cancer. Journal Of Clinical Oncology 2025, 43: 65-65. DOI: 10.1200/jco.2025.43.4_suppl.65.Peer-Reviewed Original ResearchRectal cancer survivorsCancer survivorsElixhauser Comorbidity IndexLong-term survivors of colorectal cancerSurvivors of colorectal cancerClinical prediction modelStage I-III colonCancer diagnosisGastrointestinal cancer survivorsYear 4Area-level povertyAssociated with reduced qualityRisk of frailtyProportion of residentsOnset of frailtyPredictors of frailtyFederal poverty lineIncreased risk of deathAdministrative claims codesSurvivorship managementRisk of deathRetrospective cohort studyAssociated with shorter timePatient raceSevere frailtyPredictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence.
Yasin F, Westvold S, Long J, Fan J, Hyslop T, Leeds I, Cecchini M, Gross C, Dinan M. Predictors of late recurrence of colorectal cancer (CRC) among older long-term survivors using claims-based evidence. Journal Of Clinical Oncology 2025, 43: 66-66. DOI: 10.1200/jco.2025.43.4_suppl.66.Peer-Reviewed Original ResearchCRC-specific mortalityAll-cause mortalityCancer diagnosisColorectal cancerLong-term CRC survivorsNon-cancer related conditionsNon-metastatic colorectal cancerSEER-MedicareRisk of all-cause mortalityRecurrence of colorectal cancerColon cancerSEER-Medicare populationYear 5CRC survivorsSEER-Medicare databaseSurvivorship careRectal cancerFollow-up accountsColorectal cancer recurrenceMultiple co-morbiditiesMedicare claimsRetrospective cohort studyFine-Gray modelEstimate cumulative incidencePrimary risk factor
2024
Association between mammographic screening history and stage at diagnosis among women with screen-detected breast cancer.
Huang S, Westvold S, Soulos P, Winer E, Robinson T, Dinan M. Association between mammographic screening history and stage at diagnosis among women with screen-detected breast cancer. Journal Of Clinical Oncology 2024, 20: 145-145. DOI: 10.1200/op.2024.20.10_suppl.145.Peer-Reviewed Original ResearchScreen-detected breast cancerBreast cancer mortalityScreening historyScreening mammographyScreening mammogramsCancer mortalityFee-for-service Medicare Parts ABreast cancerBreast cancer-specific mortalityScreening prior to diagnosisNon-Hispanic black raceNegative screening mammogramCohort study of womenFactors associated with increased oddsAssociated with lower riskRetrospective cohort study of womenRoutine screening mammographyMedicare Part AHigh school educationStudy of womenCancer-specific mortalityMultivariate logistic regressionSEER-Medicare databaseClaims-based algorithmSporadic screeningStrength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting
Stackland S, Schnabel D, Dinan M, Presley C, Gross C. Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting. Journal Of The National Cancer Institute 2024, 117: 144-151. PMID: 39288939, PMCID: PMC11717411, DOI: 10.1093/jnci/djae196.Peer-Reviewed Original ResearchComprehensive genomic profilingComprehensive genomic profiling testCenter for Medical Technology PolicyClinical careClinical outcomesDiagnostic testsAssessed clinical outcomesOutcomes of patientsStrength of evidenceCourse of clinical careEfficacy of diagnostic testsNovel diagnostic testsPeer-reviewed literatureGenomic profiling testsFoundationOne CDxGenomic testingSolid tumorsStudy designGenomic alterationsGenomic profilingF1CDxCancer settingClinical utilityCancer typesCompare groupsCost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service MedicareChanges in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act
Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.Peer-Reviewed Original ResearchFacility-level changesAffordable Care ActNon-expansion statesUrological cancer patientsProportion of patientsExpansion statesBaseline proportion of patientsUrologic cancer careHigh-income zip codesCancer patientsFactors associated with changesPre-post designCancer care centerPost-ACA periodMedicaid expansion statesMultivariate logistic regressionMedicaid-insured patientsCancer careUrological cancersZip codesCare ActMedicaid patientsMedicaidLogistic regressionCare centerCharacterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 207: 541-550. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factorsPersonalized risk assessment of new onset depression in long-term cancer survivors.
Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.Peer-Reviewed Original ResearchHistory of depressionIncidence of depressionCumulative incidence of depressionRisk of developing depressionLong-term survivorsPredictors of depressionCancer survivorsDisease specific factorsCumulative incidenceNon-HispanicHigher risk of developing depressionRectal cancerLong-term cancer survivorsBreast cancer survivorsCensus tract povertyColon cancerEpisodes of bipolar I disorderPrevalence of depressionMean survival time modelsDiagnosis of depressionReceipt of treatmentAssociated with prior historyHormone receptor statusPatients aged <Adjuvant endocrine therapyOpioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.Peer-Reviewed Original ResearchDocumented painHealth systemOpioid prescribingOpioid prescriptionsOpioid prescribing trendsYale New Haven Health SystemPrescribing trendsMetastatic cancerDocumented pain scoresUS health systemOpioid usePain scoresAdult patientsCalculated predicted probabilitiesFlowsheet dataRetrospective cohort studyRelated harmSolid tumor malignanciesCohort studyCancer painPrescribingContext of cancer treatmentStudy criteriaPainSurgery cohortACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure
Osazuwa-Peters O, Greiner M, Kaufman B, Zambrano Guevara L, Dinan M, Havrilesky L, Moss H. ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure. Gynecologic Oncology 2024, 187: 184-191. PMID: 38788516, DOI: 10.1016/j.ygyno.2024.05.020.Peer-Reviewed Original ResearchAccountable care organizationsGynecologic cancer patientsACO sizeYear of cancer diagnosisReceipt of healthcareLog-binomial regression modelsCancer patientsNon-ACO providersPatients seeking careAdjusted risk ratiosHealth care costsAnnual Medicare expendituresMedian household incomeAssociated with useCare organizationsOutpatient careMedicare expendituresCare costsHealthcare costsMedicare spendingCancer diagnosisOutpatient settingHousehold incomeRisk ratioMultivariable adjusted risk ratiosArea Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaArea-level measuresRenal cell carcinomaPatient-level factorsSystemic therapyEthnic disparitiesRelative risk ratiosSocially vulnerable areasCell carcinomaMeasures of social vulnerabilityMedicare beneficiariesCohort studyFee-for-service Medicare Parts AOdds ratioReceipt of systemic therapyLogistic regressionArea-level characteristicsAssociated with lack of treatmentNon-Hispanic blacksRetrospective cohort studyIndividual-level demographicsNon-Hispanic whitesAssociated with disparitiesUS Medicare beneficiariesMeasures of disadvantage
2023
Zillow MD: Do housing prices predict cancer survival?
Dinan M, Wheeler S. Zillow MD: Do housing prices predict cancer survival? JNCI Cancer Spectrum 2023, 7: pkad086. PMID: 37965909, PMCID: PMC10646759, DOI: 10.1093/jncics/pkad086.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply